Alison McKinney, WMUK’s Chief Nursing Officer, has just returned from the American Society of Haematology (ASH) Annual Conference, where WM featured in a number of sessions.
ASH is the world’s largest haematology conference, and it was really encouraging to see WM being discussed so widely. These sessions helped spark conversations about WM and WMUK, and most importantly made sure the patient voice was heard at an event largely focused on clinical practice.
WM-VOICE Project
One of the highlights was the presentation of findings from the WM-VOICE project. This is the first international study to look at what matters most to people living with WM when they’re thinking about treatment options.
The study surveyed 1,455 people with WM from the UK, the Netherlands, the USA, Australia and Canada, helping to fill an important gap in understanding patient preferences as new treatments continue to be developed.
The findings showed that while many patients liked the idea of oral treatments taken at home, what mattered most was how long a treatment works and avoiding serious or long-lasting side effects.
Importantly, people living with WM shared the same priorities regardless of where they lived. These insights can help support better conversations between patients and clinicians and make sure future research focuses on what really matters to those affected by WM.
You can download a copy of the Abstract here.
